Negative working day effect, but expect underlying growth up q-o-q. Q1 cons. looks too high: ABGSCe 5% below on adj. EBITDA. Cautious into numbers, likely better to BUY after.
Danish margins likely past trough; licences to add ~1pp to margins. Credible '26 margin target, but consensus remains unconvinced. '25e-'26e EBITDA 6-11% above cons: BUY, new TP of DKK 340.
Strong Q4 FCF and launch of buybacks took focus. More visibility on turnaround: 27% EBITDA growth in '24e. Upgrading to BUY (Hold) with new TP of DKK 285 (225).
Q4e: Another weak quarter, but enough to reach FY'23 guidance. Still expect a better '24e despite neg. 4-3% adj. EBITDA revisions, but visibility is low: HOLD into numbers, reiterate TP of DKK 225.
Q3 adds another significant earnings miss to the records; Cutting '24e-'25e adj. EBITDA by 3-2% and EPS by 8-4%; Confirming our cautious short-term view - not the time to buy; HOLD
We cut '23e adj. EBITDA by 6% and adj. EPS by 15% on higher costs. Q2 revenues surprised positively, but weaker-than-expected profitability was the focus.
Q2e: adj. EBITDA ~1% below cons. Focus on Danish demand, Intrasoft growth, and UK margins. Attractive '24e-'25e multiples, but HOLD ahead of weaker H2.